In such cancers, deletion of a region of chromosome 5q results in CK1α haploinsufficiency through loss of the CSNK1A1 gene (Kronke et al, 2015), thereby sensitizing cells against further degradation of CK1α by lenalidomide. The gene discussed is CSNK1A1; the disease is cancer.